Call for Abstracts

In the vast field of nanomedicine, “theranostics” combine therapeutics and diagnostics, aiming to provide a comprehensive platform for diagnosis, therapy, and monitoring of the patient and leading to customized approaches and personalized treatment. Emerging nanotechnology discoveries provide a unique opportunity to design and develop such combination agents, permitting the delivery of therapeutics and concurrently allowing the detection modality to be used not only before or after but also throughout the entire treatment regimen. A nanotheranostics conference is an important initiative that could provide the forum for idea exchange and discussion to create a potential high-impact nanomedicine paradigm. The ICON 2013 conference aims to provide the optimal venue to expand nanotheranostics research in a multidisciplinary environment which will bring together all the key researchers in the nanotheranostics field.

Abstract guidelines and submission at the ICON 2013 website.

Conference Topics

1. The roadmap of nanotheranostics development - Patient-oriented approach
   - Latest preclinical and clinical advances in diagnosis and treatment
   - Connectivity between traditional clinical approaches and nanotheranostics
2. Emerging challenges for nanotheranostic applications
   - Novel hypotheses, concepts and ideas supported by thorough reasoning.
3. Nanoscience technologies for theranostic approaches
   - New (bioinspired) materials and novel synthetic approaches.
   - Drug delivery across biological barriers.
   - Biofunctional and/or multimodal nanoplatforms for theranostics.
4. Emphasis session on cancer nanotheranostics
   - Nanomedicine of cancer and drug targeting.
   - Cancer detection and monitoring - Early biomarkers of malignancy.
   - Imaging in diagnosis, surgical management and treatment monitoring
5. Toxicology, regulation, and ethics
   - Toxicology considerations in the development of nanotheranostics.
   - Policy processes to foster European leadership in nanotheranostics.
   - Regulatory aspects of nanotheranostics - A new era for Pharma industry
   - Ethical considerations - Regulating nanomedicine
   - Public health economics; reimbursing nanomedicine.

Distinguished Speakers

A number of keynote presentations will be delivered by distinguished speakers in field. These include, among other,

- Kenneth A. Dawson, University College Dublin, Ireland
- Haris Doumanidis, University of Cyprus, Cyprus
- Kostas Kostarelos, UCL School of Pharmacy, United Kingdom
- Jan Mollenhauer, University of Southern Denmark, Denmark
- Jean-Michel Siaugue, Université Pierre et Marie Curie, France

See the complete list at the ICON 2013 website.